Objective: The objective of the present study was to evaluate anti-parkinsons activity of nebivolol.
Methods: Parkinson’s disease (PD) was induced by administration of rotenone (3 mg/kg/day, i.p for 21 consecutive days), and haloperidol (1 mg/kg, i.p). The symptoms of PD like tremors, akinesia, rigidity and catalepsy were evaluated. Foot shock-induced aggression (FSIA) model was used to confirm anti-parkinsonian activity. Nebivolol was administered at doses of 5, 10 and 20 mg/kg, p.o.
Results: Treatment with nebivolol significantly reduced intensity of muscular rigidity, akinesia, tremors, duration of catalepsy and increase fighting behaviour. The locomotor activity, exploratory behavior and grip strength were significantly improved by nebivolol. In rotenone model, the biochemical analysis of brain revealed the increased level of lipid peroxidation (LPO) and decreased levels of superoxide dismutase (SOD) and catalase (CAT). Treatment with nebivolol significantly reduced LPO level and restored the defensive antioxidant enzymes SOD and CAT.
Conclusion: Nebivolol may be used as a neuroprotective agent in the treatment of parkinsons disease along with standard anti-parkinson agents.